NCT00935246

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 202 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 19 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Detailed description

The purposes of this study are: 1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning) 2. To improve the success rate of escitalopram treatment response for depressed patients

Conditions

• Depression
• Continuous Antidepressant Abuse
• Adverse Reaction to Drug

Interventions

Type	Name	Description
DRUG	Escitalopram	Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose

Timeline

• Start date: 2008-12-01
• Primary completion: 2011-10-01
• Completion: 2016-12-01
• First posted: 2009-07-08
• Last updated: 2015-12-31

Locations

1 site across 1 country: South Korea